| |
| |
|
| |
|
|
|
| |
Content for site developed under the guidance of the TRACK Advisory Council.
|
|
 |
|
| |
 |
|
|
|
| | | | |
| | |
| |
|
| ACCREDITATION STATEMENT | 
Printer-friendly version |
 |
The University of Medicine and Dentistry of New Jersey (UMDNJ) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This course (ACPE #374-999-06-022-H01) qualifies for 1.0 contact hour (# 0.10 CEUs) of continuing pharmacy credit, which will be awarded upon completion of this activity.
This activity is supported by an unrestricted educational grant from sanofi-aventis U.S. | | Back to top  | | | NEEDS STATEMENT | Patients on long-term oral anticoagulant (OAC) therapy who undergo surgery are at an increased risk of bleeding. However, discontinuing and restarting OAC therapy potentially places the patient at an increased risk of thrombosis. This update discusses the use of unfractionated heparin and low-molecular-weight heparin to maintain anticoagulation before and soon after surgery in patients with atrial fibrillation, patients with mechanical heart valves, and patients with previous venous thromboembolism. | | Back to top | | | TARGET AUDIENCE | This activity has been developed for pharmacists and/or clinical pharmacists and other health care professionals who treat patients with thrombosis. | | Back to top | | | SPECIAL NEEDS | We encourage participation by all individuals. If you have any special needs, please contact Vanessa Fendt at v.fendt@elsevier.com. | | Back to top | | | PROGRAM GOAL | By reading and studying this update, participants will have reviewed the 3 main patient groups affected by bridging therapy and will understand the current pharmacologic strategies for maintaining OAC therapy before and soon after surgery. | | Back to top | | | EDUCATIONAL OBJECTIVES | At the conclusion of this educational activity, participants will be able to:
- Discuss the epidemiology and complications of bridging
- Explain the impact of bridging on an individual’s risk of thrombosis
- Discuss the 3 main patient groups affected by bridging therapy
- Explain current guidelines for use of OAC therapy
| | Back to top | | | FACULTY DISCLOSURES | As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the manufacturer(s)of any commercial products discussed during his/her presentation.
This publication may contain references to off-label/unapproved
use of medications. | Faculty Member | | Manufacturer | | Relationship | | Marc Cohen, MD, FACC | | The sanofi-aventis Group, Schering-Plough | | Grants/Research Support, Speaker’s Bureau | | Alex Spyropoulos, MD, FACP, FCCP | | The sanofi-aventis Group, Astra-Zeneca | | Grants/Research Support, served as a Consultant | | | The sanofi-aventis Group | | Speaker’s Bureau | | Ronald K. Miller, PhD | | | | nothing to disclose |
| | Back to top | | | CONTENT DEVELOPMENT | Geno J. Merli, MD, FACP, Chairman
TRACK Advisory Council
Ludwig A. Kind Professor of Medicine
Vice Chairman for Clinical Affairs
Director of the Division of Internal Medicine
Jefferson University School of Medicine
Philadelphia, Pennsylvania
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, Chairman
TRACK Advisory Council
Director
Interventional Cardiology Fellowship
Staff, Cardia, Peripheral, and Carotid Intervention
Associate Director
Cardiovascular Fellowship
Department of Cardiovascular Medicine
Cleveland Clinic Foundation
Cleveland, Ohio
Alex Spyropoulos, MD, FACP, FCCP
Founder and Medical Director
Clinical Thrombosis Center
Lovelace Sandia Health Systems
Clinical Associate Professor
Department of Medicine
Associate Professor of Pharmacy
College of Pharmacy
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
Marc Cohen, MD, FACC
Chief of the Division of Cardiology
Director of the Cardiology Fellowship
Newark Beth Israel Medical Center
Newark, New Jersey
Professor of Medicine
Mount Sinai School of Medicine
New York, New York
Cindy Jablonowski, MA
Editor
Excerpta Medica
A Division of Elsevier
Bridgewater, New Jersey | | Back to top | | | ACTIVITY DIRECTOR | Linda Spooner, PharmD
Massachusetts College of Pharmacy and Health Sciences
Worcester, Massachusetts
This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Linda Spooner, PharmD, Jennifer M. Nishioka, RPh, and A. Scott Mathis, PharmD. | | Back to top | | | UNAPPROVED/OFF-LABEL USE DISCLOSURE | Faculty may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration–approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
This program is sponsored by UMDNJ and Excerpta Medica, Inc. The opinions expressed in these pages are those of the chairmen and are not attributable to the sponsor or grantor, or to the publisher or editor.
Copyright © 2006 by Excerpta Medica, Inc., an Elsevier business. All rights reserved.
Release date: June 2006.
The Use of Heparin as Bridging Therapy When Long-term Oral Anticoagulants Are Interrupted for an Elective Procedure or Surgery | | Back to top | | |
|
| | |
|
|
| |
|
|